CureVac (NASDAQ:CVAC)

PRESS RELEASE

published on 11/04/2024 at 13:03, 1 year 4 months ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
CureVac appoints Axel Sven Malkomes as CFO, bringing 30 years of industry experience. His role will drive strategic initiatives, financial foundation, and shareholder value

Biopharmaceutical Company CFO MRNA Technology CureVac Axel Sven Malkomes
PRESS RELEASE

published on 11/04/2024 at 13:00, 1 year 4 months ago

CureVac to Present at the 12th International mRNA Health Conference
CureVac to present new data at the 12th International mRNA Health Conference, showcasing developments in mRNA cancer vaccine and lipid nanoparticle delivery technology

Innovation Biopharmaceutical CureVac MRNA Platform MRNA Health Conference
BRIEF

published on 10/28/2024 at 13:05, 1 year 4 months ago

CureVac to Present New Findings at SITC Annual Meeting

Clinical Trials MRNA Technology Cancer Vaccine CureVac SITC Meeting
PRESS RELEASE

published on 10/28/2024 at 13:00, 1 year 4 months ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CureVac to present at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, sharing immunogenicity data on mRNA-based cancer vaccine CVGBM. Conference details and contact info provided

CureVac MRNA Poster Presentation Immunogenicity Society For Immunotherapy Of Cancer
BRIEF

published on 09/13/2024 at 14:02, 1 year 6 months ago

CureVac's CVGBM Cancer Vaccine Shows Promising Results in Phase 1 Glioblastoma Study

CureVac Glioblastoma CVGBM Phase 1 Study T-cell Responses
PRESS RELEASE

published on 09/13/2024 at 13:57, 1 year 6 months ago

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
CureVac's CVGBM Cancer Vaccine induces promising immune responses in Phase 1 Study in Glioblastoma presented at ESMO 2024 Congress. Results show de novo T-cell activity & acceptable safety profile up to 100 µg dose

Cancer Vaccine CureVac CVGBM Phase 1 Study Immune Responses
BRIEF

published on 09/12/2024 at 13:02, 1 year 6 months ago

CureVac and GSK Report Positive Phase 2 Data for Influenza mRNA Vaccine

MRNA Technology Influenza Vaccine Phase 2 Results GSK Partnership CureVac Milestone
PRESS RELEASE

published on 09/12/2024 at 12:57, 1 year 6 months ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
CureVac Partner GSK reports positive Phase 2 results for seasonal influenza mRNA vaccine program. Data show immune responses to A and B strains with acceptable safety profile

GSK CureVac Phase 2 MRNA Vaccine Seasonal Influenza
BRIEF

published on 09/09/2024 at 13:05, 1 year 6 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Clinical Data CureVac MRNA Vaccine Glioblastoma ESMO Congress
PRESS RELEASE

published on 09/09/2024 at 13:00, 1 year 6 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
CureVac to present first CVGBM Glioblastoma cancer vaccine clinical data at ESMO 2024 Congress. First-in-human study results to be shared, highlighting mRNA technology's potential for cancer vaccines

MRNA Technology CureVac Glioblastoma CVGBM ESMO 2024 Congress

Published on 03/17/2026 at 08:20, 2 hours 36 minutes ago

Nano One Advances Candiac LFP Production Capacity Expansion Project, Detailed Engineering & Equipment Procurement
Published on 03/17/2026 at 08:05, 2 hours 51 minutes ago

BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
Published on 03/17/2026 at 08:01, 2 hours 55 minutes ago

Star Copper Reports First Phase 2 Drill Results Extending Mineralization to West, North and South
Published on 03/16/2026 at 22:45, 12 hours 11 minutes ago

Copper Road Announces Closing of Financing
Published on 03/16/2026 at 22:30, 12 hours 26 minutes ago

Core Silver Intersects High-Grade Copper-Molybdenum Veins up to 7.31% Cu & 1.01% Mo Confirming Large Porphyry System at Laverdiere

View all ACCESSWIRE

Published on 03/17/2026 at 10:30, 26 minutes ago

Bybit EU Cooperates with PayPal to Simplify Crypto Funding
Published on 03/17/2026 at 10:04, 52 minutes ago

Cantourage Group SE publishes preliminary figures for 2025 – Revenue rises to EUR 92.8 million
Published on 03/17/2026 at 10:02, 54 minutes ago

ETH Learning Factory Zug: A new center for learning, research and practice at Tech Cluster Zug
Published on 03/17/2026 at 10:00, 55 minutes ago

Original-Research: SMARTBROKER HOLDING AG (von GBC AG): BUY
Published on 03/17/2026 at 10:00, 56 minutes ago

Swiss Re announces USD 2 billion longevity reinsurance transaction

View all EQS

Published on 03/17/2026 at 07:00, 3 hours 56 minutes ago

Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 16 hours 56 minutes ago

Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 16 hours 58 minutes ago

Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 16 hours 59 minutes ago

Reporting on share buyback transactions carried out between March 9 and March 13, 2026
Published on 03/16/2026 at 17:45, 17 hours 11 minutes ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News